 |
0 Diseases |  |
24 Trials |
|
24 Trials |  |
921 News |  |
| «12345678910111213...1920» |
- | Rybelsus (semaglutide oral) / Novo Nordisk
New trial: Evaluating the biological activity of a single dose of encapsulated oral semaglutide in healthy adults over a period of one week. (EUDRACT) - Jun 28, 2024
P0, N=8, Not yet recruiting, Sponsor: Professor Timothy W Jones
- Anesthesia, Your Patient Is Almost Coded in the PACU After a Pituitary Surgery! Crisis Preparation and Management for Transsphenoidal Pituitary Surgery (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_3036;
Abstract is embargoed at this time.
- Anesthesia, Your Patient Is Almost Coded in the PACU After a Pituitary Surgery! Crisis Preparation and Management for Transsphenoidal Pituitary Surgery (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_479;
Abstract is embargoed at this time. Abstract is embargoed at this time.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: Sema-RTx: Semaglutide Treatment for Hyperglycaemia After Renal Transplantation (clinicaltrials.gov) - Jun 19, 2024
P4, N=104, Recruiting, Sponsor: Rigshospitalet, Denmark
Abstract is embargoed at this time. Not yet recruiting --> Recruiting
- | Rybelsus (semaglutide oral) / Novo Nordisk
Observational data, Retrospective data, Journal, Real-world evidence, Real-world: Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study). (Pubmed Central) - Jun 19, 2024
None of the participants experienced severe hypoglycemic events. Oral semaglutide in subjects with type 2 diabetes improved glycemic control and body weight in a real-world clinical setting.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Retrospective data, Journal: Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus. (Pubmed Central) - Jun 19, 2024
Semaglutide, administered orally or subcutaneously, demonstrated positive effects on body composition, metabolic and glycaemic control in patients with T2DM and obesity. This real-world study highlights the potential of bioelectrical impedance analysis in assessing antidiabetic drugs' impact on body composition, providing valuable insights for future research and clinical applications.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Oral Semaglutide in Routine Clinical Practice: Characteristics of People with Type 2 Diabetes Started on the Drug and Changes in Their Clinical Parameters after 24 Weeks of Treatment. (Pubmed Central) - Jun 19, 2024
A total of 40 patients (20.8%) discontinued treatment: 26 because of gastrointestinal adverse events, and 10 due to limited effectiveness in lowering HbA1c and/or BW. In a real clinical setting, patients initiating oral semaglutide showed suboptimal metabolic control, short diabetes duration and obesity; a significant improvement in HbA1c and BW was achieved mainly in patients with a more recent diabetes diagnosis, supporting the use of oral semaglutide in the early phase of the disease.
- || Review, Journal: Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (Pubmed Central) - Jun 18, 2024
Multiple molecules with different mechanisms of action are under development for T2D, obesity and other metabolic complications. Data on their cardio-renal benefits, long-term efficacy and safety as well as their cost-effectiveness will better inform their position in treatment algorithms.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Journal, Adverse events: Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system. (Pubmed Central) - Jun 18, 2024
Therefore, when selecting the route of administration for semaglutide, clinicians should consider the risk of adverse events and weigh them against the clinical benefits. Based on these considerations, appropriate guidance and recommendations can be provided to patients.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Retrospective data, Journal: Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis. (Pubmed Central) - Jun 14, 2024
Severe or symptomatic hypoglycemic episodes were reduced compared to positive control drugs. Oral semaglutide has definite clinical benefits of reducing blood glucose, body weight, reducing the risk of hypoglycemia, and with good safety.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Observational data, Journal, Real-world evidence, Real-world: Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes in the PIONEER REAL Netherlands Multicentre, Prospective, Observational Study. (Pubmed Central) - Jun 11, 2024
P
In this real-world population, we reported clinically significant reductions in HbA1c and BW, improved treatment satisfaction and no new safety concerns. A graphical abstract is available with this article.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open, Trial initiation date: The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial (clinicaltrials.gov) - Jun 10, 2024
P2, N=64, Recruiting, Sponsor: Odense University Hospital
A graphical abstract is available with this article. Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> Jun 2024
- | Rybelsus (semaglutide oral) / Novo Nordisk, Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly
New P1 trial: Pre-DM: Prevention of Progression of Prediabetes, Obesity and CV Risk (clinicaltrials.gov) - Jun 5, 2024
P1, N=64, Recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Journal, Adverse events: Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect. (Pubmed Central) - Jun 1, 2024
Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> Jun 2024 We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7
- | Rybelsus (semaglutide oral) / Novo Nordisk
Retrospective data, Journal, Real-world evidence, Real-world: Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study. (Pubmed Central) - Jun 1, 2024
We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 This study supports oral semaglutide as an effective option for T2D treatment, offering improved glucose control and weight management in a real-world setting.
- ||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion, Real-world evidence, Real-world: NN9924-4645: A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice (clinicaltrials.gov) - May 29, 2024
P=N/A, N=187, Completed, Sponsor: Novo Nordisk A/S
This study supports oral semaglutide as an effective option for T2D treatment, offering improved glucose control and weight management in a real-world setting. Recruiting --> Completed
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: A Research Study Comparing the Effect of Different Dosing Conditions on Blood Levels of Semaglutide in a New Tablet Composition in Healthy Participants (clinicaltrials.gov) - May 29, 2024
P1, N=121, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Completed Recruiting --> Completed
- || Rybelsus (semaglutide oral) / Novo Nordisk
Clinical, P1 data, PK/PD data, Journal: A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects. (Pubmed Central) - May 29, 2024
P1
At steady state, oral semaglutide exposure was dose dependent and close to dose proportionality in healthy Chinese subjects. This is consistent with previous clinical pharmacology results for oral semaglutide.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Journal, Adverse events, Real-world evidence, Real-world: Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023. (Pubmed Central) - May 22, 2024
The conclusions align with the technical specifications of the product. Notably, other unexpected effects are reported, including acute cholecystitis, paralysis of the abducens nerve, and positional vertigo.
- TERN-501 / Terns Pharma
TERN-501 Enhances Weight Loss Efficacy of a GLP-1R Agonist in Obese Mice via Increased Fat Mass Loss without Additional Loss of Lean Mass (Poster Hall (West A4-B2); 760) - May 20, 2024 - Abstract #ADA2024ADA_3271;
These results suggest that TERN-501, a potent and highly selective THR? agonist, may be an ideal combination partner for GLP-1 therapies.
- Rybelsus (semaglutide oral) / Novo Nordisk
Evaluating the Efficacy of Oral Semaglutide in Chinese Patients with Type 2 Diabetes by Baseline Characteristics (Poster Hall (West A4-B2); 752) - May 20, 2024 - Abstract #ADA2024ADA_3263;
agonist, may be an ideal combination partner for GLP-1 therapies. Significant reductions in HbA1c and body weight were observed with oral semaglutide across BL subgroups, including age, GI disease and HbA1c,vs comparator.
- Rybelsus (semaglutide oral) / Novo Nordisk
Oral Semaglutide in Indian Type 2 Diabetes Mellitus patients (SOLID) Study (Poster Hall (West A4-B2); 809) - May 20, 2024 - Abstract #ADA2024ADA_2842;
Significant reductions in HbA1c and body weight were observed with oral semaglutide across BL subgroups, including age, GI disease and HbA1c,vs comparator. Over a 12-month period, individuals with T2DM demonstrated significant improvements in key glycemic parameters, including HbA1c, and reduction in body weight, highlighting the potential of oral semaglutide as a first-line therapeutic option for this population.
- Rybelsus (semaglutide oral) / Novo Nordisk
Impact of Fasting on Adherence to Dosing Instructions and Efficacy of Oral Semaglutide during Ramadan in People with Type 2 Diabetes in Real-World Setting (Poster Hall (West A4-B2); 808) - May 20, 2024 - Abstract #ADA2024ADA_2841;
Over a 12-month period, individuals with T2DM demonstrated significant improvements in key glycemic parameters, including HbA1c, and reduction in body weight, highlighting the potential of oral semaglutide as a first-line therapeutic option for this population. This O-SEMA Fast sub-analysis indicated that most people adhered to oral semaglutide administration instructions and experienced significant decrease in HbA1c and body weight, making oral semaglutide as a suitable choice of drug for people who fast during Ramadan.
- Rybelsus (semaglutide oral) / Novo Nordisk
How Effective Is Weight Loss by Oral Semaglutide on Glycemic Control in a Real-World Setting? (Poster Hall (West A4-B2); 803) - May 20, 2024 - Abstract #ADA2024ADA_2835;
(Figure) This study demonstrates that oral Semaglutide effectively reduces HbA1c levels in T2DM patients, particularly in those with significant weight loss. These findings highlight its potential dual benefit in glycemic control and weight management in T2DM therapy.
- Impact of Newer GLP-1 RAs on HbA1c in U.S. Adults with Type 2 Diabetes (Poster Hall (West A4-B2); 774) - May 20, 2024 - Abstract #ADA2024ADA_2804;
Increased adoption of newer GLP-1 RAs is associated with lower average HbA1c and higher proportion of HbA1c <7% at the population level. Population-level HbA1c control was improved after the first newer GLP-1 RA approval.
- Rybelsus (semaglutide oral) / Novo Nordisk
Effect of Oral Semaglutide in Glycemic Control and Weight Reduction for People with Type 2 Diabetes Mellitus Having a BMI ?25 kg/m2 (Poster Hall (West A4-B2); 1708) - May 20, 2024 - Abstract #ADA2024ADA_2660;
In this real world study 1 in 3 T2D with obesity achieved a weight loss of 5% and 1 in 2 T2D with obesity achieved reduction in insulin dose. This study provides real-world evidence of sustainable improvements in A1C, weight, and BMI among T2D treated with oral semaglutide.
- Rybelsus (semaglutide oral) / Novo Nordisk
AdOral (Poster Hall (West A4-B2); 1677) - May 20, 2024 - Abstract #ADA2024ADA_2627;
This study provides real-world evidence of sustainable improvements in A1C, weight, and BMI among T2D treated with oral semaglutide. AdOral
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Comparison of Adherence and Persistence between Oral Semaglutide and Once-Weekly Semaglutide Injection at 12-Month Follow-up in Japanese Real-World Data (Poster Hall (West A4-B2); 1873) - May 20, 2024 - Abstract #ADA2024ADA_1829;
O-SEMA initiators showed significantly higher adherence and greater persistence on their therapy than SEMA-I initiators in 12-month. On the other hand, it is important to be cautious of the risk of treatment discontinuation in the early stages of O-SEMA administration, as the complexity of management and the method of administration may be influencing factors.
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Adjuvant Glucagon-Like Peptide 1 Receptor Agonist (GLP-1 RA) Use in HNF1A- and HNF4A-MODY (Poster Hall (West A4-B2); 1875) - May 20, 2024 - Abstract #ADA2024ADA_1523;
On the other hand, it is important to be cautious of the risk of treatment discontinuation in the early stages of O-SEMA administration, as the complexity of management and the method of administration may be influencing factors. These 4 patients (3 HNF1A-MODY, 1 HNF4A-MODY) demonstrate that adjuvant treatment with GLP-1 RA lowers HbA1c, body weight, and sulfonylurea dose requirements in patients with HNF1A- and HNF4A-MODY.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: No more needles: Oral semaglutide for weight loss. (Pubmed Central) - May 19, 2024
These 4 patients (3 HNF1A-MODY, 1 HNF4A-MODY) demonstrate that adjuvant treatment with GLP-1 RA lowers HbA1c, body weight, and sulfonylurea dose requirements in patients with HNF1A- and HNF4A-MODY. No abstract available
- || Review, Journal: Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: a revolution in the making? (Pubmed Central) - May 18, 2024
Exendin-4 (Bydureon), Liraglutide (Victoza, Saxenda) and Lixisenatide (Adlyxin), drugs that are on the market as treatments for diabetes, have shown clear effects in improving motor activity in patients with PD in phase II clinical trials...Two phase III trials testing the GLP-1 drug semaglutide (Wegovy, Ozempic, Rybelsus) are ongoing...Newer drugs that have been designed to enter the brain easier are being developed already show improved effects in preclinical studies compared with the older GLP-1 class drugs that had been developed to treat diabetes. The future looks bright for new treatments for AD and PD.
- ||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: OASIS 4: Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range (clinicaltrials.gov) - May 13, 2024
P3, N=307, Completed, Sponsor: Novo Nordisk A/S
The future looks bright for new treatments for AD and PD. Active, not recruiting --> Completed
- | Rybelsus (semaglutide oral) / Novo Nordisk
Observational data, Retrospective data, Journal, Real-world evidence, Real-world: Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study. (Pubmed Central) - May 9, 2024
Active, not recruiting --> Completed Oral semaglutide was effective in improving cardiovascular risk factors in this real-world population living with T2D, and no serious events were identified related to oral semaglutide in this patient group.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal, HEOR, Real-world evidence, Real-world: Real-World Treatment Patterns Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide. (Pubmed Central) - May 9, 2024
Oral semaglutide was effective in improving cardiovascular risk factors in this real-world population living with T2D, and no serious events were identified related to oral semaglutide in this patient group. This study provides insight for physicians and payers into the real-world prescribing practices within the first 6
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed, HEOR, Monotherapy, Real-world evidence, Real-world: A Research Study Comparing RYBELSUS (clinicaltrials.gov) - May 7, 2024
P4, N=1262, Active, not recruiting, Sponsor: Novo Nordisk A/S
This study provides insight for physicians and payers into the real-world prescribing practices within the first 6 Recruiting --> Active, not recruiting
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Efficacy and tolerability of oral semaglutide in Japanese patients with type 2 diabetes mellitus: Analysis report from diabetes specialist clinics. (Pubmed Central) - May 3, 2024
Oral semaglutide treatment demonstrates efficacy and tolerability for managing type 2 diabetes mellitus in Japan. Significant improvements in metabolic factors induced by oral semaglutide are anticipated, particularly in obese patients.
- | Rybelsus (semaglutide oral) / Novo Nordisk
Retrospective data, Journal: Improvement of ?-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis. (Pubmed Central) - May 2, 2024
Significant improvements in metabolic factors induced by oral semaglutide are anticipated, particularly in obese patients. Switching to oral semaglutide ameliorated ?-cell function compared with DPP-4is, presumably via tissue-to-tissue crosstalk between liver and ?-cells.
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III (clinicaltrials.gov) - May 1, 2024
P1, N=121, Completed, Sponsor: Novo Nordisk A/S
Switching to oral semaglutide ameliorated ?-cell function compared with DPP-4is, presumably via tissue-to-tissue crosstalk between liver and ?-cells. Recruiting --> Completed
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants (clinicaltrials.gov) - May 1, 2024
P1, N=264, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Completed Active, not recruiting --> Completed
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P4 trial, New trial, Surgery, Metastases: FLAMES: Fibrosis Lessens After Metabolic Surgery (clinicaltrials.gov) - Apr 19, 2024
P=N/A, N=120, Not yet recruiting, Sponsor: Ali Aminian
- | Rybelsus (semaglutide oral) / Novo Nordisk
Journal: Willingness to Pay (WTP) for Newer Treatment Options for Diabetes: A Study Among Patients at a Tertiary Care Centre. (Pubmed Central) - Apr 15, 2024
Conclusion This study demonstrated the feasibility of WTP assessments in an Indian outpatient setting, revealing a substantial cost disparity between patients' WTP for oral semaglutide and its market price. The findings underscore the importance of considering WTP in introducing new diabetes medications in India, offering valuable insights for healthcare decision-makers and developers.
- | Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Journal: Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials. (Pubmed Central) - Apr 15, 2024
The findings underscore the importance of considering WTP in introducing new diabetes medications in India, offering valuable insights for healthcare decision-makers and developers. No abstract available
- Rybelsus (semaglutide oral) / Novo Nordisk
Semaglutide for type 2 diabetes control in metabolic dysfunction-associated steatotic liver disease (MASLD): a two-way effect? (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_2115;
No abstract available In 62 consecutive overweight/obese T2D pts with MASLD (age 61.4
- Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
Efficacy and safety of incretin-based therapies in patients with metabolic dysfunction-associated steatotic liver disease complicated by type 2 diabetes mellitus (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_2104;
Background and Aims: The aim of this study was to evaluate the efficacy and safety of oral semaglutide (Sema), a GLP-1 receptor agonist, and tirzepatide (TZP), a dual GIP/GLP-1 receptor agonist, in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) complicated by type 2 diabetes mellitus (T2DM)... Both Sema and TZP treatments offered a favorable effect on MASLD as well as improving diabetic status and reducing body weight.
- Rybelsus (semaglutide oral) / Novo Nordisk, Rezdiffra (resmetirom) / Madrigal Pharma
Synergistic hepatoprotective effects of semaglutide and resmetirom combination therapy in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1144;
Further therapeutic benefits are achieved by combination treatment, demonstrating the feasibility of combined stimulation of GLP-1R and THR-? receptor function to improve outcomes in MASH.
- Rybelsus (semaglutide oral) / Novo Nordisk, DA-1241 - Dong / A
Additive hepatoprotective effects of DA-1241, a novel GPR119 agonist, in combination with semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1115;
GAN DIO-MASH mice received once daily treatment with vehicle, DA-1241 (100 mg/kg, PO) or semaglutide (30 nmol/kg, SC) alone or in combination for 8 weeks. DA-1241 and semaglutide demonstrate more than additive effects on metabolic, biochemical, and histological endpoints in GAN DIO-MASH mice, highlighting the therapeutic potential of dual targeting GPR119 and GLP1R function in MASH with liver fibrosis.
- Clinical translatability of the GAN diet-induced obese and biopsy-confirmed mouse model of MASH (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1091;
agonist, 10 mg/kg, PO, QD), firsocostat (ACC inhibitor, 5 mg/kg, PO, QD), or vehicle for 12 weeks. GAN DIO-MASH mice faithfully reproduce histological outcomes of several compounds profiled in clinical trials for MASH, highlighting clinical translatability and utility of the model in preclinical drug development.
- Rybelsus (semaglutide oral) / Novo Nordisk, DA-1241 - Dong / A
DA-1241, a GPR119 agonist, combined with Semaglutide synergistically improved liver fibrosis in mice with CCl4-induced liver fibrosis (Poster Area) - Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_915;
After administering CCl 4 twice weekly for 3 weeks, mice with elevated plasma ALT levels were allocated to receive DA-1241 (oral) or semaglutide (subcutaneous) alone and in combination for 4 weeks. For the first time, we suggest a beneficial combination effect of DA-1241 and semaglutide in the treatment of liver fibrosis, which may be attributed to augmented inhibition of fibrogenesis and inflammation in the liver.
- | Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Trial completion, Trial completion date: Semaglutide in Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Apr 2, 2024
P4, N=180, Completed, Sponsor: Zagazig University
For the first time, we suggest a beneficial combination effect of DA-1241 and semaglutide in the treatment of liver fibrosis, which may be attributed to augmented inhibition of fibrogenesis and inflammation in the liver. Recruiting --> Completed | Trial completion date: Aug 2024 --> Apr 2024
- || Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk, Trulicity (dulaglutide) / Eli Lilly
Retrospective data, Review, Journal: A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists. (Pubmed Central) - Apr 1, 2024
Additionally, semaglutide, dulaglutide, and liraglutide were beneficial in terms of composite renal outcomes: These GLP-1 RAs were significantly associated with less new or persistent macroalbuminuria, but not with improved eGFR deterioration or reduced requirement for renal replacement therapy. However, GLP-1 RAs may benefit patients with type 2 diabetes mellitus or obesity.